OMOgnyan Mladenov

Ognyan Mladenov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ognyan Mladenov has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological, Optical, and Combined Approaches to Myopia Control in Bulgarian Children: A Longitudinal Study

    by G. Dimitrov, G. Dimitrova, A. Levi, N. Veleva, O. Mladenov, Y. Kaneva, A. Oscar

    This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.

  • Open Access

    Screening outcomes and treatment patterns of retinopathy of prematurity in Bulgaria: Emerging role of anti-VEGF therapy

    by Alexander Oscar, Yani Zdravkov, Ognyan Mladenov, Valentina Tomova, Ralitza Georgieva, Vasil Haykin

    A retrospective analysis of premature infants screened for retinopathy of prematurity (ROP) in Sofia between 2019 and 2023 included 660 infants. ROP was diagnosed in 145 infants (21.97%). Treatment was required in 97 infants (14.7% of all screened). Laser photocoagulation was performed in 80 infants (82.5% of treated cases), whereas intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with aflibercept was administered in 17 infants (17.5%), mainly in posterior or aggressive disease. Spontaneous regression occurred in 48 infants (33.1%). No cases of endophthalmitis or systemic adverse events were observed after anti-VEGF therapy. Lower gestational age and birth weight were strongly associated with disease occurrence. These findings indicate that ROP remains a significant clinical challenge in premature infants, whereas pharmacological VEGF inhibition represents an important therapeutic option in selected severe cases, complementing conventional laser treatment.